search
Back to results

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

Primary Purpose

Multiple Myeloma

Status
Recruiting
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Elranatamab + Nirogacestat
Elranatamab + lenalidomide + dexamethasone
Sponsored by
Pfizer
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Multiple Myeloma focused on measuring PF-06863135, Multiple Myeloma, BCMA, elranatamab, bispecific antibody, MagnetisMM-4

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody

  • Measurable disease defined by at least one of the following:

    1. Serum M-protein >/= 0.5 g/dL by SPEP
    2. Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
    3. Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • ECOG performance status 0 -1
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1

Exclusion Criteria:

  • Active plasma cell leukemia
  • Amyloidosis
  • Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
  • POEMS syndrome
  • Any active uncontrolled bacterial, fungal, or viral infection
  • Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
  • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
  • Sub-Study A Only: Previous treatment with BCMA bispecific antibody
  • Sub-Study B Only: Previous treatment with BCMA directed therapy

Sites / Locations

  • Banner Gateway Medical CenterRecruiting
  • Banner MD Anderson Cancer CenterRecruiting
  • University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer InstituteRecruiting
  • Beverly Hills Cancer CenterRecruiting
  • Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaDRecruiting
  • Cedars Sinai Medical CenterRecruiting
  • Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)Recruiting
  • Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical CenterRecruiting
  • Sylvester Comprehensive Cancer Center- Deerfield BeachRecruiting
  • Sylvester Comprehensive Cancer CenterRecruiting
  • UHealth TowerRecruiting
  • UChicago Medicine - River EastRecruiting
  • University of Chicago Medical CenterRecruiting
  • UChicago Medicine at Ingalls - FlossmoorRecruiting
  • UChicago Medicine Ingalls MemorialRecruiting
  • University of Chicago Comprehensive Cancer Center at Silver Cross HospitalRecruiting
  • The University of Chicago Medicine Center for Advanced Care Orland ParkRecruiting
  • UChicago Medicine at Ingalls - Tinley ParkRecruiting
  • University of Iowa Hospitals and ClinicsRecruiting
  • The University of Kansas Cancer Center ,Investigational Drug ServicesRecruiting
  • The University of Kansas Clinical Research CenterRecruiting
  • The University of Kansas Hospital Investigational Drug ServicesRecruiting
  • The University of Kansas HospitalRecruiting
  • The University of Kansas Medical Center Medical Office BuildingRecruiting
  • University of Kansas Hospital Cambridge North Tower ARecruiting
  • The University of Kansas Cancer Center - Indian Creek CampusRecruiting
  • The University of Kansas Cancer CenterRecruiting
  • OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsRecruiting
  • The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)Recruiting
  • Massachusetts General HospitalRecruiting
  • Beth Israel Deaconess Medical Center
  • Beth Israel Deaconess Medical CenterRecruiting
  • Beth Israel Deaconess Medical Center
  • Beth Israel Deaconess Medical CenterRecruiting
  • Nebraska Medicine - Bellevue Medical CenterRecruiting
  • Nebraska Medicine - Nebraska Medical CenterRecruiting
  • Nebraska Medicine - Cancer Center at Village Pointe Health CenterRecruiting
  • University Of Nebraska Medical Center
  • University Of Nebraska Medical CenterRecruiting
  • Tom Baker Cancer CenterRecruiting
  • The Ottawa Hospital - General CampusRecruiting
  • Princess Margaret Cancer CentreRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Sub-Study A

Sub-Study B

Arm Description

BCMA-CD3 bispecific antibody + gamma secretase inhibitor

BCMA-CD3 bispecific antibody + immunomodulatory drug

Outcomes

Primary Outcome Measures

Sub-Study A Phase 1: Dose Limiting Toxicity
Number of participants with Dose Limiting Toxicity
Sub-Study A Phase 2: Objective Response Rate
Objective response rate (IMWG response criteria)
Sub-Study B Phase 1 Escalation: Dose Limiting Toxicity
Number of participants with Dose Limiting Toxicity
Sub-Study B Phase 1 Expansion: Frequency of Treatment-Emergent Adverse Events
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Sub-Study B Phase 1 Expansion: Frequency of Laboratory Abnormalities
Type and severity per NCI CTCAE v5

Secondary Outcome Measures

Sub-Study A Phase 1: Objective Response Rate
Objective response rate (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Complete Response Rate
Complete response rate (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Time to Response
Time to response (IMWG criteria)
Sub-Study A Phase 1 and 2: Duration of Response
Duration of response (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Duration of Complete Response
Duration of complete response (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Progression Free Survival
Progression free survival (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Overall Survival
Overall survival
Sub-Study A Phase 1 and Phase 2: Minimal Residual Disease Negativity Rate
Minimal residual disease negativity rate (IMWG response criteria)
Sub-Study A Phase 1 and Phase 2: Frequency of Treatment-Emergent Adverse Events
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Sub-Study A Phase 1 and Phase 2: Frequency of Laboratory Abnormalities
Type and severity per NCI CTCAE v5
Sub-Study A Phase 1 and Phase 2: Immunogenicity of elranatamab in combination with nirogacestat
Anti-drug antibodies and neutralizing antibodies against elranatamab
Sub-Study A Phase 1 and Phase 2: Concentrations of elranatamab and/or nirogacestat
Pre-dose and post-dose concentrations of elranatamab; pre-dose concentrations of nirogacestat
Sub-Study A Phase 1: Maximum Observed Concentration (Cmax) for elranatamab
Cmax for elranatamab administration
Sub-Study A Phase 1: Time to Maximum Concentration (Tmax) for elranatamab
Tmax for elranatamab administration
Sub-Study A Phase 1: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab
AUClast for elranatamab administration
Sub-Study B Phase 1 Escalation: Frequency of Treatment-Emergent Adverse Events
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Sub-Study B Phase 1 Escalation: Frequency of Laboratory Abnormalities
Type and severity per NCI CTCAE v5
Sub-Study B Phase 1 Escalation and Expansion: Objective Response Rate
Objective response rate (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Complete Response Rate
Complete response rate (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Time to Response
Time to response (IMWG criteria)
Sub-Study B Phase 1 Escalation and Expansion: Duration of Response
Duration of response (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Duration of Complete Response
Duration of complete response (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Progression Free Survival
Progression free survival (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Overall Survival
Overall survival
Sub-Study B Phase 1 Escalation and Expansion: Minimal Residual Disease Negativity Rate
Minimal residual disease negativity ratio (IMWG response criteria)
Sub-Study B Phase 1 Escalation and Expansion: Immunogenicity of elranatamab in combination with lenalidomide
Anti-drug antibodies and neutralizing antibodies against elranatamab
Sub-Study B Phase 1 Escalation and Expansion: Concentrations of elranatamab and/or lenalidomide
Pre-dose and post-dose concentrations of elranatamab, pre-dose concentrations of lenalidomide
Sub-Study B Phase 1 Escalation and Expansion: Maximum Observed Concentrations (Cmax) for elranatamab
Cmax for elranatamab administration
Sub-Study B Phase 1 Escalation and Expansion: Time to Maximum Concentration (Tmax) for elranatamab
Tmax for elranatamab administration
Sub-Study B Phase 1 Escalation and Expansion: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab
AUClast for elranatamab administration

Full Information

First Posted
October 8, 2021
Last Updated
October 4, 2023
Sponsor
Pfizer
search

1. Study Identification

Unique Protocol Identification Number
NCT05090566
Brief Title
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
Official Title
A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
Study Type
Interventional

2. Study Status

Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
October 27, 2021 (Actual)
Primary Completion Date
March 3, 2025 (Anticipated)
Study Completion Date
September 24, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Pfizer

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Multiple Myeloma
Keywords
PF-06863135, Multiple Myeloma, BCMA, elranatamab, bispecific antibody, MagnetisMM-4

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
105 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Sub-Study A
Arm Type
Experimental
Arm Description
BCMA-CD3 bispecific antibody + gamma secretase inhibitor
Arm Title
Sub-Study B
Arm Type
Experimental
Arm Description
BCMA-CD3 bispecific antibody + immunomodulatory drug
Intervention Type
Drug
Intervention Name(s)
Elranatamab + Nirogacestat
Other Intervention Name(s)
PF-06863135
Intervention Description
BCMA-CD3 bispecific antibody + gamma secretase inhibitor
Intervention Type
Drug
Intervention Name(s)
Elranatamab + lenalidomide + dexamethasone
Other Intervention Name(s)
PF-06863135; Revlimid
Intervention Description
BCMA-CD3 bispecific antibody + immunomodulatory
Primary Outcome Measure Information:
Title
Sub-Study A Phase 1: Dose Limiting Toxicity
Description
Number of participants with Dose Limiting Toxicity
Time Frame
35 days
Title
Sub-Study A Phase 2: Objective Response Rate
Description
Objective response rate (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation: Dose Limiting Toxicity
Description
Number of participants with Dose Limiting Toxicity
Time Frame
42 days
Title
Sub-Study B Phase 1 Expansion: Frequency of Treatment-Emergent Adverse Events
Description
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Time Frame
assessed for approximately 2 years
Title
Sub-Study B Phase 1 Expansion: Frequency of Laboratory Abnormalities
Description
Type and severity per NCI CTCAE v5
Time Frame
assessed every cycle (each cycle approximately 28 days)
Secondary Outcome Measure Information:
Title
Sub-Study A Phase 1: Objective Response Rate
Description
Objective response rate (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Complete Response Rate
Description
Complete response rate (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Time to Response
Description
Time to response (IMWG criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and 2: Duration of Response
Description
Duration of response (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Duration of Complete Response
Description
Duration of complete response (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Progression Free Survival
Description
Progression free survival (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Overall Survival
Description
Overall survival
Time Frame
assessed for approximately 2 years
Title
Sub-Study A Phase 1 and Phase 2: Minimal Residual Disease Negativity Rate
Description
Minimal residual disease negativity rate (IMWG response criteria)
Time Frame
assessed approximately every 12 months (for approximately 2 years)
Title
Sub-Study A Phase 1 and Phase 2: Frequency of Treatment-Emergent Adverse Events
Description
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Time Frame
assessed for approximately 2 years
Title
Sub-Study A Phase 1 and Phase 2: Frequency of Laboratory Abnormalities
Description
Type and severity per NCI CTCAE v5
Time Frame
assessed every cycle (each cycle approximately 28 days)
Title
Sub-Study A Phase 1 and Phase 2: Immunogenicity of elranatamab in combination with nirogacestat
Description
Anti-drug antibodies and neutralizing antibodies against elranatamab
Time Frame
assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)
Title
Sub-Study A Phase 1 and Phase 2: Concentrations of elranatamab and/or nirogacestat
Description
Pre-dose and post-dose concentrations of elranatamab; pre-dose concentrations of nirogacestat
Time Frame
assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)
Title
Sub-Study A Phase 1: Maximum Observed Concentration (Cmax) for elranatamab
Description
Cmax for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)
Title
Sub-Study A Phase 1: Time to Maximum Concentration (Tmax) for elranatamab
Description
Tmax for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)
Title
Sub-Study A Phase 1: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab
Description
AUClast for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)
Title
Sub-Study B Phase 1 Escalation: Frequency of Treatment-Emergent Adverse Events
Description
Type and severity per NCI CTCAE v5 (CRS and ICANS assessed per ASTCT criteria)
Time Frame
assessed for approximately 2 years
Title
Sub-Study B Phase 1 Escalation: Frequency of Laboratory Abnormalities
Description
Type and severity per NCI CTCAE v5
Time Frame
assessed every cycle (each cycle approximately 28 days)
Title
Sub-Study B Phase 1 Escalation and Expansion: Objective Response Rate
Description
Objective response rate (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Complete Response Rate
Description
Complete response rate (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Time to Response
Description
Time to response (IMWG criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Duration of Response
Description
Duration of response (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Duration of Complete Response
Description
Duration of complete response (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Progression Free Survival
Description
Progression free survival (IMWG response criteria)
Time Frame
assessed every 4 weeks (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Overall Survival
Description
Overall survival
Time Frame
assessed for approximately 2 years
Title
Sub-Study B Phase 1 Escalation and Expansion: Minimal Residual Disease Negativity Rate
Description
Minimal residual disease negativity ratio (IMWG response criteria)
Time Frame
assessed approximately every 12 months (for approximately 2 years)
Title
Sub-Study B Phase 1 Escalation and Expansion: Immunogenicity of elranatamab in combination with lenalidomide
Description
Anti-drug antibodies and neutralizing antibodies against elranatamab
Time Frame
assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)
Title
Sub-Study B Phase 1 Escalation and Expansion: Concentrations of elranatamab and/or lenalidomide
Description
Pre-dose and post-dose concentrations of elranatamab, pre-dose concentrations of lenalidomide
Time Frame
assessed approximately every 1 to 3 cycles (each cycle approximately 28 days)
Title
Sub-Study B Phase 1 Escalation and Expansion: Maximum Observed Concentrations (Cmax) for elranatamab
Description
Cmax for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)
Title
Sub-Study B Phase 1 Escalation and Expansion: Time to Maximum Concentration (Tmax) for elranatamab
Description
Tmax for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)
Title
Sub-Study B Phase 1 Escalation and Expansion: Area Under the Concentration versus Time Curve from Time 0 to the Last Measurable Concentration (AUClast) for elranatamab
Description
AUClast for elranatamab administration
Time Frame
assessed after first elranatamab dose (approximately 3-7 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody Measurable disease defined by at least one of the following: Serum M-protein >/= 0.5 g/dL by SPEP Urinary M-protein excretion >/= 200 mg/24 hours by UPEP Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio ECOG performance status 0 -1 Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1 Exclusion Criteria: Active plasma cell leukemia Amyloidosis Stem cell transplant with 12 weeks prior to enrollment, or active GVHD POEMS syndrome Any active uncontrolled bacterial, fungal, or viral infection Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer) Sub-Study A Only: Previous treatment with BCMA bispecific antibody Sub-Study B Only: Previous treatment with BCMA directed therapy
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pfizer CT.gov Call Center
Phone
1-800-718-1021
Email
ClinicalTrials.gov_Inquiries@pfizer.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pfizer CT.gov Call Center
Organizational Affiliation
Pfizer
Official's Role
Study Director
Facility Information:
Facility Name
Banner Gateway Medical Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Recruiting
Facility Name
Banner MD Anderson Cancer Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Arkansas for Medical Sciences - Winthrop P. Rockefeller Cancer Institute
City
Little Rock
State/Province
Arkansas
ZIP/Postal Code
72205
Country
United States
Individual Site Status
Recruiting
Facility Name
Beverly Hills Cancer Center
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Individual Site Status
Recruiting
Facility Name
Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaD
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Name
Cedars Sinai Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Name
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)
City
Los Angeles
State/Province
California
ZIP/Postal Code
90048
Country
United States
Individual Site Status
Recruiting
Facility Name
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
City
Coral Gables
State/Province
Florida
ZIP/Postal Code
33146
Country
United States
Individual Site Status
Recruiting
Facility Name
Sylvester Comprehensive Cancer Center- Deerfield Beach
City
Deerfield Beach
State/Province
Florida
ZIP/Postal Code
33442
Country
United States
Individual Site Status
Recruiting
Facility Name
Sylvester Comprehensive Cancer Center
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Name
UHealth Tower
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Individual Site Status
Recruiting
Facility Name
UChicago Medicine - River East
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Chicago Medical Center
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60637
Country
United States
Individual Site Status
Recruiting
Facility Name
UChicago Medicine at Ingalls - Flossmoor
City
Flossmoor
State/Province
Illinois
ZIP/Postal Code
60422
Country
United States
Individual Site Status
Recruiting
Facility Name
UChicago Medicine Ingalls Memorial
City
Harvey
State/Province
Illinois
ZIP/Postal Code
60426
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital
City
New Lenox
State/Province
Illinois
ZIP/Postal Code
60451
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Chicago Medicine Center for Advanced Care Orland Park
City
Orland Park
State/Province
Illinois
ZIP/Postal Code
60462
Country
United States
Individual Site Status
Recruiting
Facility Name
UChicago Medicine at Ingalls - Tinley Park
City
Tinley Park
State/Province
Illinois
ZIP/Postal Code
60477
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Iowa Hospitals and Clinics
City
Iowa City
State/Province
Iowa
ZIP/Postal Code
52242
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Cancer Center ,Investigational Drug Services
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Clinical Research Center
City
Fairway
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Hospital Investigational Drug Services
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66103
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Hospital
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Medical Center Medical Office Building
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Name
University of Kansas Hospital Cambridge North Tower A
City
Kansas City
State/Province
Kansas
ZIP/Postal Code
66160
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Cancer Center - Indian Creek Campus
City
Overland Park
State/Province
Kansas
ZIP/Postal Code
66211
Country
United States
Individual Site Status
Recruiting
Facility Name
The University of Kansas Cancer Center
City
Westwood
State/Province
Kansas
ZIP/Postal Code
66205
Country
United States
Individual Site Status
Recruiting
Facility Name
OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
Individual Site Status
Recruiting
Facility Name
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21231
Country
United States
Individual Site Status
Recruiting
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Individual Site Status
Recruiting
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
Individual Site Status
Recruiting
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Beth Israel Deaconess Medical Center
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Individual Site Status
Recruiting
Facility Name
Nebraska Medicine - Bellevue Medical Center
City
Bellevue
State/Province
Nebraska
ZIP/Postal Code
68123
Country
United States
Individual Site Status
Recruiting
Facility Name
Nebraska Medicine - Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68105
Country
United States
Individual Site Status
Recruiting
Facility Name
Nebraska Medicine - Cancer Center at Village Pointe Health Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68118
Country
United States
Individual Site Status
Recruiting
Facility Name
University Of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University Of Nebraska Medical Center
City
Omaha
State/Province
Nebraska
ZIP/Postal Code
68198
Country
United States
Individual Site Status
Recruiting
Facility Name
Tom Baker Cancer Center
City
Calgary
State/Province
Alberta
ZIP/Postal Code
T2N4N2
Country
Canada
Individual Site Status
Recruiting
Facility Name
The Ottawa Hospital - General Campus
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H 8L6
Country
Canada
Individual Site Status
Recruiting
Facility Name
Princess Margaret Cancer Centre
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 2M9
Country
Canada
Individual Site Status
Recruiting

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
IPD Sharing URL
https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests
Links:
URL
https://pmiform.com/clinical-trial-info-request?StudyID=C1071004
Description
To obtain contact information for a study center near you, click here.

Learn more about this trial

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

We'll reach out to this number within 24 hrs